In this report, the Pertussis Infection Testing Market has been segmented by Product Type, Dignosis, End Users, and Geography.

Pertussis Infection Testing Market, Segmentation by Product Type

The Pertussis Infection Testing Market has been segmented by Product Type into Reagents and Kits, Bordetella Pertussis IgM ELISA Test, Instruments, FluoroType Bordetella and PCR Instruments.

Reagents and Kits
The Reagents and Kits segment leads the market, holding approximately 45% of the global share. These components are essential for a variety of diagnostic procedures such as PCR assays, ELISA tests, and antigen detection methods, all of which are critical for accurate and timely diagnosis of pertussis. The increasing demand for rapid, high-precision testing solutions continues to drive the need for premium-quality reagents and kits. As healthcare facilities and diagnostic laboratories scale up their testing infrastructure, the growth trajectory of this segment is expected to remain strong.

Bordetella Pertussis IgM ELISA Test
Segment also captures a substantial portion of the market, contributing nearly 25% to the overall share. This diagnostic method targets the detection of IgM antibodies specific to Bordetella pertussis, making it particularly valuable for diagnosing infections in their later stages. The test is highly regarded for its sensitivity and effectiveness in identifying past infections, and it is often utilized in regions with high vaccination rates. However, because IgM ELISA tests have limited effectiveness in detecting early-stage infections, they are frequently used alongside PCR-based molecular diagnostics to ensure comprehensive and accurate pertussis detection.

Instruments segment,
Encompassing both FluoroType Bordetella and PCR Instruments, is witnessing robust expansion, representing roughly 30% of the global market. Innovative technologies such as FluoroType Bordetella leverage fluorescence-based PCR techniques to deliver rapid and highly accurate detection of Bordetella pertussis DNA. These advanced solutions offer quicker results compared to traditional PCR methods while maintaining high sensitivity and specificity. PCR Instruments continue to be indispensable tools for early-stage diagnosis, especially for detecting infections in asymptomatic individuals. The growing adoption of molecular diagnostic platforms in clinical laboratories, coupled with the rising demand for early and reliable pertussis diagnosis, is fueling substantial growth in this segment.

Pertussis Infection Testing Market, Segmentation by Diagnosis

The Pertussis Infection Testing Market has been segmented by Diagnosis into Blood Tests, Chest X-Ray, Nose or Throat Culture Test, and Other Diagnosis Types.

Blood Tests: Leading the Diagnostic Segment
Blood tests dominate the pertussis infection testing market by diagnosis type, accounting for approximately 45% of the global share. Blood tests, particularly serological assays detecting IgM and IgG antibodies against Bordetella pertussis, are critical for confirming recent or past infections. These tests are highly valued for their accuracy in cases where symptoms may be atypical or mild, especially among vaccinated individuals. Their ability to support rapid screening and complement molecular diagnostics has made blood tests a preferred choice across hospitals, diagnostic laboratories, and specialty clinics worldwide.

Chest X-Ray: Supporting Clinical Assessment
Chest X-ray diagnostics represent about 20% of the market share within pertussis diagnosis. Although not used to directly detect Bordetella pertussis, chest X-rays are crucial in identifying lung inflammation or complications arising from pertussis infections, such as pneumonia. Physicians often recommend chest X-rays when severe respiratory symptoms are present, helping differentiate pertussis from other respiratory illnesses. The demand for chest X-rays in pertussis diagnosis is expected to remain steady, particularly in settings where advanced laboratory testing is not immediately available.

Nose or Throat Culture Test: Traditional yet Reliable
Nose or throat culture tests contribute around 25% to the overall diagnostic segment. These traditional methods involve collecting a sample from the nasopharynx and culturing it to detect the presence of Bordetella pertussis. Although the process takes longer—typically several days—culture testing is still considered the gold standard for definitive pertussis diagnosis in certain cases. It is especially important in epidemiological studies and outbreak investigations where high specificity is critical. Advances in transport media and culture techniques have slightly improved the turnaround time, maintaining relevance for culture testing in modern clinical settings.

Other Diagnosis Types: Emerging Innovations
Other diagnosis types, including rapid antigen detection tests and emerging molecular diagnostic innovations, make up the remaining 10% of the market. Rapid diagnostic tests offer faster results, typically within a few hours, and are increasingly deployed in point-of-care (POC) settings. Newer molecular techniques, such as multiplex PCR panels, are also gaining traction for their ability to simultaneously detect multiple respiratory pathogens, including pertussis. The growing need for quick and accurate diagnostic solutions, especially in resource-limited environments, is expected to boost the share of these emerging diagnostic methods in the coming years.

Pertussis Infection Testing Market, Segmentation by End Users

The Pertussis Infection Testing Market has been segmented by End Users into Hospitals, Specialty Clinics, Diagnostic Laboratories and Research Centers.

Hospitals: Dominating the End-User Segment
Hospitals account for approximately 50% of the pertussis infection testing market by end users, making them the largest segment. Their dominance is attributed to their robust infrastructure, access to skilled healthcare professionals, and advanced diagnostic equipment. Hospitals are typically the first point of care for patients with suspected pertussis infections, especially in severe cases involving infants or immunocompromised individuals. With access to a full range of diagnostic tests—including PCR assays, serological tests, and rapid antigen detection—hospitals ensure accurate and timely diagnosis. The increasing investment by hospitals in cutting-edge diagnostic technologies aimed at improving detection rates is expected to further fuel growth in this segment.

Specialty Clinics: Rising Role in Pertussis Diagnosis
Specialty clinics contribute nearly 25% of the pertussis infection testing market share among end users. These clinics, particularly those focusing on pediatrics, respiratory care, and infectious diseases, play a crucial role in diagnosing and managing pertussis, especially among high-risk groups such as infants, the elderly, and pregnant women. Specialty clinics offer rapid diagnostic services using PCR-based assays and rapid antigen detection tests, enabling early intervention and treatment. The growing emphasis on pediatric healthcare and the increasing incidence of pertussis infections in vulnerable populations are expected to boost demand for pertussis testing services in specialty clinic settings.

Diagnostic Laboratories: Ensuring Comprehensive Testing Solutions
Diagnostic laboratories, including commercial labs and academic research institutions, hold about 20% of the market share. These facilities are pivotal in offering high-quality, reliable testing using advanced technologies such as PCR instruments, IgM ELISA tests, and traditional culture-based methods. As healthcare providers and public health agencies intensify their surveillance of respiratory diseases, the demand for comprehensive pertussis testing through diagnostic laboratories is surging. The laboratories' capacity to deliver large volumes of accurate results plays an essential role in supporting public health initiatives and outbreak management strategies.

Research Centers: Driving Innovation in Diagnostics
Although smaller in market share, accounting for approximately 5%, research centers play an outsized role in shaping the future of the pertussis infection testing market. These institutions focus on developing new diagnostic technologies, refining existing methods, and studying the epidemiology of Bordetella pertussis. Research centers contribute significantly to innovations such as faster PCR techniques, improved antigen detection methods, and novel vaccine development. Their contributions are vital for enhancing diagnostic accuracy, enabling earlier detection, and ultimately supporting global efforts to reduce pertussis-related morbidity and mortality.

Pertussis Infection Testing Market, Segmentation by Geography

In this report, the Pertussis Infection Testing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Pertussis Infection Testing Market Share (%), by Geographical Region

North America: Leading the Global Market
North America holds the largest share of the pertussis infection testing market, accounting for approximately 40% of the overall revenue. The market’s dominance is fueled by advanced healthcare infrastructure, high public awareness regarding pertussis, and the presence of leading diagnostic companies. The United States is the major growth driver, supported by widespread vaccination campaigns, a relatively high incidence of pertussis among infants and elderly populations, and the rapid adoption of advanced diagnostics such as PCR assays and ELISA tests. The region’s robust healthcare system, coupled with the widespread availability of molecular diagnostic tools in hospitals and specialty clinics, continues to boost market expansion.

Europe: Strong Focus on Early Detection and Vaccination
Europe represents approximately 30% of the pertussis infection testing market. Growth in this region is driven by strong healthcare systems, rigorous regulatory standards, and increasing governmental efforts to raise vaccination coverage and enhance disease surveillance. Major economies like Germany, the United Kingdom, and France are spearheading advancements, with many healthcare institutions incorporating advanced diagnostic techniques such as PCR-based testing. Supportive initiatives from the European Union to monitor infectious diseases and the heightened demand for accurate diagnostic solutions are key factors propelling the market forward across Europe.

Asia Pacific: Fastest Growing Regional Market
The Asia Pacific region is poised to achieve the fastest growth rate in the pertussis infection testing market, expected to grow at a compound annual growth rate (CAGR) of over 8% during the forecast period. Countries like China, India, and Japan are leading this growth, driven by rising healthcare investments, an increasing burden of pertussis, and better access to modern diagnostic technologies. Factors such as rapid urbanization, greater healthcare awareness, and expanding healthcare infrastructure are significantly boosting adoption rates of pertussis testing across the region. As diagnostic capabilities continue to improve, Asia Pacific is set to emerge as a major contributor to global market revenues.

Middle East, Africa, and Latin America: Emerging Markets with Steady Growth
The Middle East and Africa and Latin America collectively contribute around 15% of the pertussis infection testing market. Although these regions currently experience moderate growth compared to North America and Asia Pacific, ongoing improvements in healthcare access, public health initiatives, and infectious disease control programs are gradually strengthening their market presence. Economic challenges and historically lower vaccination rates have somewhat limited progress; however, a growing focus on disease surveillance and expanding availability of diagnostic technologies are expected to fuel future demand. As healthcare infrastructures in these regions continue to develop, opportunities for pertussis infection testing providers are expected to steadily increase.